Subscribe to Newsletter

Carsten Brockmeyer

The Power List 2016

Carsten Brockmeyer

Chief Executive Officer, Formycon

Carsten has been working with the biosimilars industry from the very beginning; he was involved in the development of Binocrit (epoetin alfa), the world’s first complex biosimilar anemia drug. He was headhunted for the role at Formycon after holding a one-day workshop on biosimilars at the company. 

Part of the Power List 2016

The Top 100

The nominations are in and after considerable debate and analysis from our judging panel, we present The Power List 2016 – our second foray into the Top 100 most influential people in the world of drug development and manufacture.

Go to The Power List 2016

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine